Table 2.

Baseline Clinical Variables of African American Patients with RA from the CLEAR Registry^*

Variable	Total Cohort			Subset with Radiographic Scores
	CLEAR I n=357	CLEAR II n=418	p value†	CLEAR I n=294	CLEAR II n=167	p value†
HAQ‡ Score, median (IQ 25–75)	1.8 (0.0–2.4)	2.0 (0.0–3.0)	0.0037	1.8 (0.9–2.4)	2.0 (1.3–2.5)	0.0509
JAM § Score, median (IQ 25–75)	4.0 (0.0–14.0)	2.0 (0.0–14.0)	0.0313	4.0 (0.0–14.0)	2.0 (0.0–13.0)	0.1381
Number of tender joints, median (IQ 25–75)	8.0 (2.0–19.0)	6.0 (2.0–14.0)	0.0286	7.0 (2.0–18.0)	5.0 (2.0–12.0)	0.0786
Number of swollen joints, median (IQ 25– 75)	4.0 (1.0–10.0)	5.0 (1.0–12)	0.1642	4.0 (1.0–8.0)	5.0 (0.0–13.0)	0.2681
Pain scale¶ (0–10 cm), median (IQ 25–75)	7.0 (4.0–8.0)	7.0 (5.0–8.0)	0.3062	7.0 (4.0–8.0)	7.0 (4.0–9.0)	0.5795
Laboratory
Rheumatoid factor, % positive	80.1	79.7	0.8953	77.3	84.1	0.1080
Anti-CCP** antibodies, % positive	63.4	75.1	0.0007	61.3	80.0	<0.0001
Medications
Glucocorticoids, ever used%	77.8	79.9	0.4713	79.3	80.9	0.6833
DMARDs††, current use%	81.8	83.3	0.5930	84.4	83.8	0.8828
Methotrexate, current use%	62.5	61.6	0.8026	63.6	66.0	0.6057

^*The CLEAR Registry is still actively collecting radiographs at 36 months and 60 months in CLEAR I and at study entry in CLEAR II. Thus, radiographic scores are not available for all subjects at the present time;

^†p-value calculated by Chi-square or Wilcoxon Rank-sum;

^‡Health Assessment Questionnaire;

^§Joint Alignment and Motion;

^¶Pain scale (0–10);

^**Anti-cyclic citrullinated peptide second generation;

^††Disease- modifying anti-rheumatic drugs (DMARDs) (shown in Appendix 1).